Suppr超能文献

肝内胆管癌的分子发病机制的新见解。

New insights into the molecular pathogenesis of intrahepatic cholangiocarcinoma.

机构信息

Departments of Transplantation and Cancer Biology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA,

出版信息

J Gastroenterol. 2014 Feb;49(2):165-72. doi: 10.1007/s00535-013-0894-y. Epub 2013 Oct 22.

Abstract

Intrahepatic cholangiocarcinoma is an aggressive malignancy and is one of the most devastating cancers of the gastrointestinal tract. The molecular mechanisms contributing to the pathogenesis of these cancers are not well understood. The recognition and distinction of these cancers from other tumors such as perihilar or extrahepatic distal cholangiocarcinoma and hepatocellular carcinoma are important in defining the pathogenesis. New insights into molecular mechanisms contributing to disease pathogenesis are emerging from recent epidemiological, genome-wide profiling and laboratory based studies. These have contributed to an improved understanding of risk factors, genetic mutations and pathophysiological mechanisms that are associated with these tumors. The contribution of well-established risk factors such as biliary tract inflammation and key signaling pathways involved in intrahepatic cholangiocarcinoma are being further defined. These new insights have several important implications for both molecular diagnosis and therapy of these cancers.

摘要

肝内胆管癌是一种侵袭性恶性肿瘤,是胃肠道最具破坏性的癌症之一。导致这些癌症发生的分子机制尚不清楚。从其他肿瘤(如肝门周围或肝外远端胆管癌和肝细胞癌)中识别和区分这些癌症对于确定发病机制很重要。最近的流行病学、全基因组分析和实验室基础研究为疾病发病机制的分子机制提供了新的认识。这些研究有助于更好地了解与这些肿瘤相关的危险因素、基因突变和病理生理机制。正在进一步明确胆道炎症等既定危险因素以及参与肝内胆管癌的关键信号通路的作用。这些新的认识对这些癌症的分子诊断和治疗都有重要意义。

相似文献

1
New insights into the molecular pathogenesis of intrahepatic cholangiocarcinoma.
J Gastroenterol. 2014 Feb;49(2):165-72. doi: 10.1007/s00535-013-0894-y. Epub 2013 Oct 22.
2
The molecular pathogenesis of cholangiocarcinoma.
Semin Liver Dis. 2004 May;24(2):127-37. doi: 10.1055/s-2004-828890.
3
Intrahepatic cholangiocarcinoma: current management and emerging therapies.
Expert Rev Gastroenterol Hepatol. 2017 May;11(5):439-449. doi: 10.1080/17474124.2017.1309290. Epub 2017 Mar 29.
4
Cholangiocarcinoma.
Surg Pathol Clin. 2018 Jun;11(2):403-429. doi: 10.1016/j.path.2018.02.005.
5
Will advanced cholangiocarcinoma become a targetable malignancy?
Crit Rev Oncol Hematol. 2021 Mar;159:103233. doi: 10.1016/j.critrevonc.2021.103233. Epub 2021 Jan 19.
6
Mechanisms of biliary carcinogenesis and growth.
World J Gastroenterol. 2008 May 21;14(19):2986-9. doi: 10.3748/wjg.14.2986.
7
[Gallbladder and bile duct carcinoma. Biology and pathology].
Internist (Berl). 2004 Jan;45(1):33-41. doi: 10.1007/s00108-003-1110-6.
8
Role of epigenetic alterations in cholangiocarcinoma.
J Hepatobiliary Pancreat Surg. 2006;13(4):274-9. doi: 10.1007/s00534-005-1055-3.
9
Cholangiocarcinoma: new insights into disease pathogenesis and biology.
Infect Dis Clin North Am. 2010 Dec;24(4):871-84, vii. doi: 10.1016/j.idc.2010.07.006.
10
Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.
J Hepatol. 2020 Aug;73(2):315-327. doi: 10.1016/j.jhep.2020.03.008. Epub 2020 Mar 12.

引用本文的文献

2
Implication of Ferroptosis in Cholangiocarcinoma: A Potential Future Target?
Cancer Manag Res. 2023 Apr 8;15:335-342. doi: 10.2147/CMAR.S406150. eCollection 2023.
5
Long Noncoding RNA GAS5 Accelerates Cholangiocarcinoma Progression by Regulating hsa-miR-1297.
Cancer Manag Res. 2021 Mar 23;13:2745-2753. doi: 10.2147/CMAR.S297868. eCollection 2021.
6
8
Therapeutic Potential of Autophagy Modulation in Cholangiocarcinoma.
Cells. 2020 Mar 4;9(3):614. doi: 10.3390/cells9030614.
10
Hypercalcemia related to cholangiocellular carcinoma.
Clin Case Rep. 2019 Jul 1;7(8):1542-1544. doi: 10.1002/ccr3.2286. eCollection 2019 Aug.

本文引用的文献

1
A critical role for notch signaling in the formation of cholangiocellular carcinomas.
Cancer Cell. 2013 Jun 10;23(6):784-95. doi: 10.1016/j.ccr.2013.04.019. Epub 2013 May 30.
2
Identification of targetable FGFR gene fusions in diverse cancers.
Cancer Discov. 2013 Jun;3(6):636-47. doi: 10.1158/2159-8290.CD-13-0050. Epub 2013 Apr 4.
3
Cholangiocarcinoma among offset colour proof-printing workers exposed to 1,2-dichloropropane and/or dichloromethane.
Occup Environ Med. 2013 Jul;70(7):508-10. doi: 10.1136/oemed-2012-101246. Epub 2013 Mar 14.
4
Asbestos: a hidden player behind the cholangiocarcinoma increase? Findings from a case-control analysis.
Cancer Causes Control. 2013 May;24(5):911-8. doi: 10.1007/s10552-013-0167-3. Epub 2013 Feb 14.
5
Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions.
Hum Pathol. 2013 Jul;44(7):1216-22. doi: 10.1016/j.humpath.2012.11.006. Epub 2013 Feb 4.
6
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies.
Oncogene. 2013 Oct 10;32(41):4861-70. doi: 10.1038/onc.2012.617. Epub 2013 Jan 14.
7
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.
Gastroenterology. 2013 Apr;144(4):829-40. doi: 10.1053/j.gastro.2013.01.001. Epub 2013 Jan 4.
8
Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes.
J Clin Invest. 2012 Nov;122(11):3914-8. doi: 10.1172/JCI63065.
9
Classification, diagnosis, and management of cholangiocarcinoma.
Clin Gastroenterol Hepatol. 2013 Jan;11(1):13-21.e1; quiz e3-4. doi: 10.1016/j.cgh.2012.09.009. Epub 2012 Sep 13.
10
Cholangiocarcinomas can originate from hepatocytes in mice.
J Clin Invest. 2012 Aug;122(8):2911-5. doi: 10.1172/JCI63212. Epub 2012 Jul 17.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验